ReWalk Robotics Ltd (RWLK)
(Delayed Data from NSDQ)
$3.76 USD
+0.05 (1.35%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.74 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.76 USD
+0.05 (1.35%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.74 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
ReWalk Robotics (RWLK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ReWalk (RWLK) delivered earnings and revenue surprises of 28.57% and 0.15%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of 8.33% and 18.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Robotics & Automation Gaining Momentum: 4 Stocks in Focus
by Shilpa Mete
Robotics continues to boom as it aids automation. Here's a peek into four stocks that are well-poised to capitalize on growth prospects related to robotics technology.
ReWalk Robotics (RWLK) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
ReWalk (RWLK) delivered earnings and revenue surprises of 12.50% and 38.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ViewRay (VRAY) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of -6.67% and 0.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Treace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 0% and 6.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Artivion (AORT) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Artivion (AORT) delivered earnings and revenue surprises of 166.67% and 2.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ReWalk Robotics (RWLK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
ReWalk (RWLK) delivered earnings and revenue surprises of -28.57% and 3.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Dynatronics Corporation (DYNT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dynatronics Corporation (DYNT) delivered earnings and revenue surprises of -80% and 0.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
IRadimed (IRMD) Q4 Earnings Top Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 3.23% and 0.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ReWalk Robotics (RWLK) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
ReWalk (RWLK) delivered earnings and revenue surprises of -50% and 51.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Veracyte (VCYT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of 50% and 12.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Integer (ITGR) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 6.74% and 0.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ReWalk Robotics (RWLK) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
ReWalk (RWLK) delivered earnings and revenue surprises of -75% and 32.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Eli Lilly (LLY) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of -30.56% and 5.91%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Edwards Lifesciences (EW) Matches Q2 Earnings Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0% and 1.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ReWalk Robotics (RWLK) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
ReWalk (RWLK) delivered earnings and revenue surprises of -40% and 60.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 0% and 7.43%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Si-Bone (SIBN) delivered earnings and revenue surprises of -20.93% and 0.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Silk Road Medical (SILK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Silk Road Medical (SILK) delivered earnings and revenue surprises of -17.07% and 5.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Masimo (MASI) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 1.09% and 3.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Accuray (ARAY) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of 83.33% and 3.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ReWalk Robotics (RWLK) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
ReWalk (RWLK) delivered earnings and revenue surprises of -50% and 30.62%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ReWalk Robotics (RWLK) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
ReWalk (RWLK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
All You Need to Know About ReWalk (RWLK) Rating Upgrade to Buy
by Zacks Equity Research
ReWalk (RWLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).